株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の免疫グロブリン市場:原発性免疫不全症(PI)・慢性炎症性脱髄性多発性神経障害(CIDP)向けの需要が、アルツハイマー病向け認可で潜在的に補完される見通し

Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer's Disease

発行 GBI Research 商品コード 214250
出版日 ページ情報 英文 134 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GBI Research社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
世界の免疫グロブリン市場:原発性免疫不全症(PI)・慢性炎症性脱髄性多発性神経障害(CIDP)向けの需要が、アルツハイマー病向け認可で潜在的に補完される見通し Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer's Disease
出版日: 2013年05月14日 ページ情報: 英文 134 Pages
概要

世界の主要7ヶ国(米国・フランス・ドイツ・イタリア・スペイン・英国・日本)の免疫グロブリン市場は、2012年に36億米ドルの規模に達し、また2006年からの年平均(CAGR)成長率は約6%を記録しました。2019年の市場規模は58億米ドル、2012〜2019年の市場成長率は平均6.9%、2019年の市場規模は58億米ドルと予想されています。

当レポートでは、世界の主要国の免疫グロブリン市場について調査分析し、市場の収益、地域別動向、治療環境、疾患別パイプライン動向とともに、上市済み製品と参入企業のプロファイルなどをまとめ、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 市場概要

  • 収益
  • 年間治療費
  • 市場促進因子と阻害因子

第4章 地域別環境

  • 米国(収益、年間治療費)
  • 欧州主要5ヶ国(収益、年間治療費)
  • 日本(収益、年間治療費)

第5章 治療環境

  • 主な治療指標:米国・欧州・英国・日本の場合
  • 主な治療指標別の収益シェア
  • 原発性免疫不全(PI)
  • ギラン・バレー症候群
  • 慢性リンパ性白血病
  • 慢性炎症性脱髄性多発性神経障害(CIDP)
  • 重症筋無力症
  • 多巣性運動ニューロパチー
  • 特発性血小板減少性紫斑病

第6章 上市済み製品プロファイル

  • 概要
  • Privigen
  • Gammagard S/D
  • Gammagard Liquid
  • Octagam 5%
  • Flebogamma 10% DIF
  • Gamunex-C
  • Gammaplex
  • HyQvia
  • Bivigam

第7章 パイプライン分析

  • 研究開発(R&D)パイプライン
  • 主なパイプライン製品のプロファイル
    • IVIG3I Grifols 10%
    • RI-002 (IVIG)

第8章 競合環境(事業内容、近年の動向)

  • Baxter International Inc.
  • Biotest Pharmaceuticals
  • Bio Products Laboratory Ltd.
  • CSL Behring Limited
  • Grifols S.A.
  • Octapharma AG

第9章 企業合併・買収(M&A)およびライセンシング契約環境

  • 企業合併・買収(M&A)取引
  • 研究開発(R&D)ライセンシング契約

第10章 アジア太平洋地域・中国市場

  • インド
  • 中国
  • オーストラリア

第11章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GBIHC295MR

Summary

GBI Research's report "Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer's Disease"s provides in-depth analysis of the global immunoglobulin market. The report analyzes the markets for immunoglobulin products in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan. The revenue and annual cost of therapy are forecast for the key geographies and in seven key therapeutic segments, along with epidemiology data, until 2019. The seven key therapeutic segments are Primary Immunodeficiency (PI), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), Guillain-Barre Syndrome (GBS), Myasthenia Gravis (MG), Idiopathic Thrombocytopenic Purpura (ITP), and Chronic Lymphocytic Leukemia (CLL). The report also profiles the marketed products, key pipeline products, and leading companies that could change the market landscape in the forecast period.

The report has been built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research expects the immunoglobulin market to see a slight increase in its growth rate during the 2012-2019 forecast period. It was worth $3.6 billion in 2012, having grown at a Compound Annual Growth Rate (CAGR) of 6% from 2006. Demand for immunoglobulin products continues to increase due to growing disease awareness and therapeutic usage in a wide range of therapeutic areas. Immunology and neurology are the disciplines that use the most immunoglobulins, while PI and CIDP are the top indications. Geographically, the US is the largest market, commanding a share of over 70% of the global market. 11 new products have been approved in the US since 2006, but as many are for PI or ITP, immunoglobulin usage in the US remains off-label for all other indications.

Baxter, CSL Behring, and Grifols continue to command the top ranks in terms of revenue, and recent approvals of Subcutaneous Immunoglobulins (SCIGs) in the US and Europe will further boost market growth.

Scope

  • Annualized market data for the immunoglobulin market from 2006 to 2012 and forecast to 2019
  • Analysis of the seven key therapeutic segments: PI, CIDP, MMN, MG, CLL, GBS and ITP
  • Analysis of the immunoglobulins markets in the leading global geographies: the US, the top five European countries, and Japan
  • Market characterization of the immunoglobulin market, covering size, revenue analysis by geography, annual cost of therapy, and epidemiology
  • Key drivers and barriers that have a significant impact on the market
  • Coverage of key marketed products, approved indications, and safety and efficacy profiles
  • Coverage of the pipeline molecules in various phases of drug development
  • Competitive profiling of the leading companies: Baxter, Biotest, Bio Products Laboratory, CSL Behring, Grifols, and Octapharma
  • Key M&A activity and licensing agreements between 2012 and mid-2013 in the global immunoglobulin market
  • Overview of the immunoglobulin markets in Asia-Pacific and China, covering regulations, key players and marketed products

Reasons to buy

  • Align your product portfolio to the markets with high growth potential
  • Develop market-entry and market-expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
  • Develop key strategic initiatives by understanding the key focus areas of the leading companies
  • Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

Executive Summary

Immunoglobulins Market in Top Seven Markets is Estimated to Reach $5.8 Billion by 2019

The market for immunoglobulin in the top seven markets stood at $3.6 billion in 2012, having grown at a Compound Annual Growth Rate (CAGR) of 6% from 2006. It is estimated to grow at a CAGR of 6.9% to $5.8 billion by 2019. It is dominated by two indications which account for 60% of Intravenous Immunoglobulin (IVIG) usage. In terms of regional markets, the US accounts for the largest share with 71.4%, followed by the top five countries in Europe (the UK, Germany, France, Italy and Spain) with 24.3% and Japan with 4.3%. Following a high number of product approvals between 2003 and late 2012, the US market witnessed a growth rate of 5.7% from $1.8 billion in 2006 to $2.6 billion in 2012, and is estimated to reach $4 billion by 2019.

The immunoglobulin market in the top seven markets is estimated to grow at a slightly higher growth rate in the forecast period due to continuing demand for immunoglobulin treatment for several indications, rising disease awareness, approval of existing IVIG products for new indications, the expected approval of new Subcutaneous Immunoglobulin (SCIG) and global blood product shortages.

Continuing Demand from Major Indications and Approval of Subcutaneous Immunoglobulin to Give Slight Boost to the Market

In terms of replacement therapy, Primary Immunodeficiency (PI) accounts for the highest IVIG consumption with 32%, and for long-term treatment, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) accounts for the highest with 28%. PI is an indication for which all existing IVIG products have received approval from both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The FDA has approved only one product for CIDP, namely Gamunex-C in 2008, while the EMA has approved three products since 2004. The IVIG market for PI grew at a CAGR of 10.7% from 2006 to $1.2 billion in 2012 and is estimated to grow at 11% from 2012 to $2.4 billion in 2019. Since 2006, the FDA has approved five IVIG products and two SCIG products for the treatment of PI, the latest being IVIG Bivigam by Biotest in December 2012. Only one product has been approved for CIDP since 2008 in the US market, which accounts for a large share of the global market. This is reflected in a lower growth rate of 4% from 2006 to $1.0 billion by 2012. However, this segment is expected to maintain its growth rate to reach $1.4 billion by 2019, accounting for 24% of the total immunoglobulin market.

Two SCIG products, CSL's Vivaglobin and Hizentra, received approval for PI in the US in 2006 and 2011 respectively, while Gammanorm was approved by the EMA in 2005 for PI, Immune Thrombocytopenic Purpura (ITP), Guillain-Barre Syndrome (GBS) and Chronic Lymphocyte Leukemia (CLL). Another SCIG product, Baxter's HyQvia, also received a positive opinion from the EMA for marketing authorization in Europe for PI in March 2013. The trend towards SCIG is also reflected in the product pipelines. CSL's NextGen 16% for PI and Hizentra for CIDP are two SCIG products in late-stage clinical trials, while Baxter's SCIG is under investigation for approval for PI in the US.

Possible Approval of Immunoglobulin for Alzheimer's Disease Could Double the Growth Rate

The use of immunoglobulin as a treatment option for Alzheimer's disease is being investigated by all major companies in this segment, and the product pipeline is dominated by R&D in Phase II and III clinical trials. The recently completed Phase III study results of Baxter's Gammagard Liquid are anticipated in mid-2013. Similarly, Octapharma completed a Phase II study of its Octagam 10% IVIG for Alzheimer's disease and published positive results in January 2013. With a significant number of Alzheimer's patients awaiting better treatment options, the approval of either of these products could change the immunoglobulin market landscape.

Table of Contents

1 Table of Contents 5

  • 1.1 List of Tables 8
  • 1.2 List of Figures 11

2 Immunoglobulins Market to 2019 - Introduction 12

  • 2.1 Overview 12

3 Immunoglobulins Market to 2019 - Market Overview 13

  • 3.1 Revenue 13
  • 3.2 Annual Cost of Therapy 14
  • 3.3 Immunoglobulins Market Drivers and Restraints 15
    • 3.3.1 Market Drivers 15
    • 3.3.2 Restraints 16

4 Immunoglobulins Market to 2019 - Geographical Landscape 17

  • 4.1 US 17
    • 4.1.1 Revenue 17
    • 4.1.2 Annual Cost of Therapy 19
  • 4.2 Top Five European Countries 20
    • 4.2.1 Revenue 20
    • 4.2.2 Annual Cost of Therapy 22
  • 4.3 Japan 23
    • 4.3.1 Revenue 23
    • 4.3.2 Annual Cost of Therapy 24

5 Immunoglobulins Market to 2019 - Therapeutic Landscape 25

  • 5.1 Main Therapeutic Indications 25
    • 5.1.1 Indicated Conditions for Intravenous Immunoglobulin Usage - US 25
    • 5.1.2 Indications for Intravenous Immunoglobulin Usage - Europe 25
    • 5.1.3 Guidelines for Intravenous Immunoglobulin Usage - UK 26
    • 5.1.4 Indications for Intravenous Immunoglobulin Usage - Japan 26
  • 5.2 Revenue Share for the Major Therapeutic Indications 27
  • 5.3 Primary Immunodeficiency Market 28
    • 5.3.1 Introduction 28
    • 5.3.2 Revenue 29
    • 5.3.3 Annual Cost of Therapy 31
    • 5.3.4 Epidemiology 33
    • 5.3.5 Current Use 35
    • 5.3.6 Geographical Segmentation 36
  • 5.4 Guillain-Barre Syndrome Market 37
    • 5.4.1 Introduction 37
    • 5.4.2 Revenue 38
    • 5.4.3 Annual Cost of Therapy 39
    • 5.4.4 Epidemiology 40
    • 5.4.5 Current Use for Therapies 41
    • 5.4.6 Geographical Segmentation 42
  • 5.5 Chronic Lymphocytic Leukemia Market 44
    • 5.5.1 Introduction 44
    • 5.5.2 Revenue 45
    • 5.5.3 Annual Cost of Therapy 46
    • 5.5.4 Epidemiology 47
    • 5.5.5 Current Use 48
    • 5.5.6 Geographical Segmentation 49
  • 5.6 Chronic Inflammatory Demyelinating Polyneuropathy Market 51
    • 5.6.1 Introduction 51
    • 5.6.2 Revenue 52
    • 5.6.3 Annual Cost of Therapy 53
    • 5.6.4 Epidemiology 54
    • 5.6.5 Current Use 55
    • 5.6.6 Geographical Segmentation 56
  • 5.7 Myasthenia Gravis Market 58
    • 5.7.1 Introduction 58
    • 5.7.2 Revenue 59
    • 5.7.3 Annual Cost of Therapy 60
    • 5.7.4 Epidemiology 61
    • 5.7.5 Current Use 62
    • 5.7.6 Geographical Segmentation 63
  • 5.8 Multifocal Motor Neuropathy Market 65
    • 5.8.1 Introduction 65
    • 5.8.2 Revenue 66
    • 5.8.3 Annual Cost of Therapy 67
    • 5.8.4 Epidemiology 68
    • 5.8.5 Current Use 69
    • 5.8.6 Geographical Segmentation 70
  • 5.9 Idiopathic Thrombocytopenic Purpura 72
    • 5.9.1 Introduction 72
    • 5.9.2 Revenue 73
    • 5.9.3 Annual Cost of Therapy 74
    • 5.9.4 Epidemiology 75
    • 5.9.5 Current Use 76
    • 5.9.6 Geographical Segmentation 77

6 Immunoglobulins Market to 2019 - Profiles of Marketed Products 79

  • 6.1 Overview 79
  • 6.2 Privigen 81
    • 6.2.1 Overview 81
    • 6.2.2 Approved Indications 81
    • 6.2.3 Safety 81
    • 6.2.4 Efficacy 82
  • 6.3 Gammagard S/D 83
    • 6.3.1 Overview 83
    • 6.3.2 Approved Indications 83
    • 6.3.3 Safety 83
    • 6.3.4 Efficacy 84
  • 6.4 Gammagard Liquid 85
    • 6.4.1 Overview 85
    • 6.4.2 Approved Indications 85
    • 6.4.3 Safety 85
    • 6.4.4 Efficacy 86
  • 6.5 Octagam 5% 87
    • 6.5.1 Overview 87
    • 6.5.2 Approved Indications 87
    • 6.5.3 Safety 87
    • 6.5.4 Efficacy 88
  • 6.6 Flebogamma 10% DIF 88
    • 6.6.1 Overview 88
    • 6.6.2 Approved Indications 88
    • 6.6.3 Safety 88
    • 6.6.4 Efficacy 88
  • 6.7 Gamunex-C 89
    • 6.7.1 Overview 89
    • 6.7.2 Approved Indications 89
    • 6.7.3 Safety 89
    • 6.7.4 Efficacy 90
  • 6.8 Gammaplex 91
    • 6.8.1 Overview 91
    • 6.8.2 Approved Indications 91
    • 6.8.3 Safety 91
    • 6.8.4 Efficacy 92
  • 6.9 HyQvia 93
    • 6.9.1 Overview 93
    • 6.9.2 Approved Indications 93
    • 6.9.3 Safety 93
    • 6.9.4 Efficacy 93
  • 6.10 Bivigam 94
    • 6.10.1 Overview 94
    • 6.10.2 Approved Indications 94
    • 6.10.3 Safety 94
    • 6.10.4 Efficacy 94

7 Immunoglobulins Market to 2019 - Pipeline Analysis 95

  • 7.1 Research and Development Pipeline 95
  • 7.2 Major Pipeline Product Profiles 97
    • 7.2.1 IVIG3I Grifols 10% 97
    • 7.2.2 RI-002 (IVIG) 98

8 Immunoglobulins Market to 2019 - Competitive Landscape 99

  • 8.1 Baxter International Inc. 99
    • 8.1.1 Business Description 99
    • 8.1.2 Recent Developments 100
  • 8.2 Biotest Pharmaceuticals 101
    • 8.2.1 Business Description 101
    • 8.2.2 Recent Developments 101
  • 8.3 Bio Products Laboratory Ltd. 102
    • 8.3.1 Business Description 102
    • 8.3.2 Recent Developments 102
  • 8.4 CSL Behring Limited 103
    • 8.4.1 Business Description 103
    • 8.4.2 Recent Developments 103
  • 8.5 Grifols S.A. 104
    • 8.5.1 Business Description 104
    • 8.5.2 Recent Developments 105
  • 8.6 Octapharma AG 106
    • 8.6.1 Business Description 106
    • 8.6.2 Recent Developments 106

9 Immunoglobulins Market to 2019 - M&A and Licensing Deals Landscape 107

  • 9.1 M&A Deals 107
    • 9.1.1 Grifols Buys 60% of Progenika Biopharma 107
    • 9.1.2 Grifols Acquires 40% of the Capital of Biotechnology Firm VCN Bioscience 107
    • 9.1.3 Grifols Purchases Three Plasma Donation Centers in the US from Canada's Cangene 107
    • 9.1.4 Baxter Enhances Renal Therapies Portfolio with Acquisition of Gambro 107
  • 9.2 R&D Licensing Agreements 108
    • 9.2.1 Baxter and Onconova Announce European Licensing Agreement for Anti-Cancer Compound Rigosertib 108
    • 9.2.2 Baxter Announces Collaboration with Sanquin to Expand Capacity for Plasma Therapies 108
    • 9.2.3 Baxter Announces 20 Year Partnership with Hemobras in Brazil 108

10 Immunoglobulins Market to 2019 - Asia-Pacific and China 109

  • 10.1 India 109
    • 10.1.1 Overview 109
    • 10.1.2 Regulatory Landscape 109
    • 10.1.3 National Institute for Biologicals 110
    • 10.1.4 Marketed Products 110
    • 10.1.5 Product Profiles 113
    • 10.1.6 Company Profiling 114
  • 10.2 China 118
    • 10.2.1 Overview 118
    • 10.2.2 Regulatory Information 118
    • 10.2.3 Marketed Products 120
    • 10.2.4 Company Profiling 121
  • 10.3 Australia 123
    • 10.3.1 Overview 123
    • 10.3.2 Regulatory Landscape 125
    • 10.3.3 Marketed Products 126
    • 10.3.4 Product Profiles 127
    • 10.3.5 Company Profiling 128

11 Global Immunoglobulins Market: Appendix 129

  • 11.1 Market Definitions 129
  • 11.2 Abbreviations 129
  • 11.3 References 130
  • 11.4 Research Methodology 132
    • 11.4.1 Coverage 132
    • 11.4.2 Secondary Research 133
    • 11.4.3 Primary Research 133
    • 11.4.4 Expert Panel Validation 133
  • 11.5 Contact Us 134
  • 11.6 Disclaimer 134

List of Tables

  • Table 1: Immunoglobulins Market, Top Seven Markets, Revenue ($bn), 2006-2012 13
  • Table 2: Immunoglobulins Market, Top Seven Markets, Revenue Forecast ($bn), 2012-2019 13
  • Table 3: Immunoglobulins Market, Top Seven Markets, Annual Cost of Therapy ($), 2006-2012 14
  • Table 4: Immunoglobulins Market, Top Seven Markets, Annual Cost of Therapy Forecast ($), 2012-2019 14
  • Table 5: Immunoglobulins Market, US, Revenue ($bn), 2006-2012 17
  • Table 6: Immunoglobulins Market, US, Revenue Forecast ($bn), 2012-2019 17
  • Table 7: Immunoglobulins Market, US, Annual Cost of Therapy ($), 2006-2012 19
  • Table 8: Immunoglobulins Market, US, Annual Cost of Therapy Forecast ($), 2012-2019 19
  • Table 9: Immunoglobulins Market, Top Five European Countries, Revenue ($m), 2006-2012 20
  • Table 10: Immunoglobulins Market, Top Five European Countries, Revenue Forecast ($m), 2012-2019 21
  • Table 11: Immunoglobulins Market, Top Five European Countries, Annual Cost of Therapy ($), 2006-2012 22
  • Table 12: Immunoglobulins Market, Top Five European Countries, Annual Cost of Therapy Forecast ($), 2012-2019 22
  • Table 13: Immunoglobulins Market, Japan, Revenue ($m), 2006-2012 23
  • Table 14: Immunoglobulins Market, Japan, Revenue Forecast ($m), 2012-2019 23
  • Table 15: Immunoglobulins Market, Japan, Annual Cost of Therapy ($), 2006-2012 24
  • Table 16: Immunoglobulins Market, Japan, Annual Cost of Therapy Forecast ($), 2012-2019 24
  • Table 17: Immunoglobulins Market, US, Approved Indications for IVIG Usage, 2012 25
  • Table 18: Immunoglobulins Market, EU, Indicated Conditions for IVIG Usage, 2012 25
  • Table 19: Immunoglobulins Market, UK, Guidelines for IVIG Usage, 2012 26
  • Table 20: Immunoglobulins Market, Top Seven Markets, PI, Revenue ($bn), 2006-2012 29
  • Table 21: Immunoglobulins Market, Top Seven Markets, PI, Revenue Forecast ($bn), 2012-2019 29
  • Table 22: Immunoglobulins Market, Top Seven Markets, PI, Annual Cost of Therapy ($), 2006-2012 31
  • Table 23: Immunoglobulins Market, Top Seven Markets, PI, Annual Cost of Therapy Forecast ($), 2012-2019 31
  • Table 24: Immunoglobulins Market, Top Seven Markets, PI, Epidemiology, 2006-2012 33
  • Table 25: Immunoglobulins Market, Top Seven Markets, PI, Epidemiology Forecast, 2012-2019 33
  • Table 26: Immunoglobulins Market, Top Seven Markets, PI, Geographical Revenue ($m), 2006-2012 36
  • Table 27: Immunoglobulins Market, Top Seven Markets, PI, Geographical Revenue Forecast ($m), 2012-2019 36
  • Table 28: Immunoglobulins Market, Top Seven Markets, GBS, Revenue ($m), 2006-2012 38
  • Table 29: Immunoglobulins Market, Top Seven Markets, GBS, Revenue Forecast ($m), 2012-2019 38
  • Table 30: Immunoglobulins Market, Top Seven Markets, GBS, Annual Cost of Therapy ($), 2006-2012 39
  • Table 31: Immunoglobulins Market, Top Seven Markets, GBS, Annual Cost of Therapy Forecast ($), 2012-2019 39
  • Table 32: Immunoglobulins Market, Top Seven Markets, GBS, Epidemiology, 2006-2012 40
  • Table 33: Immunoglobulins Market, Top Seven Markets, GBS, Epidemiology Forecast, 2012-2019 40
  • Table 34: Immunoglobulins Market, Top Seven Markets, GBS, Geographical Revenue ($m), 2006-2012 42
  • Table 35: Immunoglobulins Market, Top Seven Markets, GBS, Geographical Revenue Forecast ($m), 2012-2019 43
  • Table 36: Immunoglobulins Market, Top Seven Markets, CLL, Revenue ($m), 2006-2012 45
  • Table 37: Immunoglobulins Market, Top Seven Markets, CLL, Revenue Forecast ($m), 2012-2019 45
  • Table 38: Immunoglobulins Market, Top Seven Markets, CLL, Annual Cost of Therapy ($), 2006-2012 46
  • Table 39: Immunoglobulins Market, Top Seven Markets, CLL, Annual Cost of Therapy Forecast ($), 2012-2019 46
  • Table 40: Immunoglobulins Market, Top Seven Markets, CLL, Epidemiology, 2006-2012 47
  • Table 41: Immunoglobulins Market, Top Seven Markets, CLL, Epidemiology Forecast, 2012-2019 47
  • Table 42: Immunoglobulins Market, Top Seven Markets, CLL, Geographical Revenue ($m), 2006-2012 49
  • Table 43: Immunoglobulins Market, Top Seven Markets, CLL, Geographical Revenue Forecast ($m), 2012-2019 50
  • Table 44: Immunoglobulins Market, Top Seven Markets, CIDP, Revenue ($m), 2006-2012 52
  • Table 45: Immunoglobulins Market, Top Seven Markets, CIDP, Revenue Forecast ($m), 2012-2019 52
  • Table 46: Immunoglobulins Market, Top Seven Markets, CIDP, Annual Cost of Therapy ($), 2006-2012 53
  • Table 47: Immunoglobulins Market, Top Seven Markets, CIDP, Annual Cost of Therapy Forecast ($), 2012-2019 53
  • Table 48: Immunoglobulins Market, Top Seven Markets, CIDP, Epidemiology, 2006-2012 54
  • Table 49: Immunoglobulins Market, Top Seven Markets, CIDP, Epidemiology Forecast, 2012-2019 54
  • Table 50: Immunoglobulins Market, Top Seven Markets, CIDP, Geographical Revenue ($m), 2006-2012 56
  • Table 51: Immunoglobulins Market, Top Seven Markets, CIDP, Geographical Revenue Forecast ($m), 2012-2019 57
  • Table 52: Immunoglobulins Market, Top Seven Markets, MG, Revenue ($m), 2006-2012 59
  • Table 53: Immunoglobulins Market, Top Seven Markets, MG, Revenue Forecast ($m), 2012-2019 59
  • Table 54: Immunoglobulins Market, Top Seven Markets, MG, Annual Cost of Therapy ($), 2006-2012 60
  • Table 55: Immunoglobulins Market, Top Seven Markets, MG, Annual Cost of Therapy Forecast ($), 2012-2019 60
  • Table 56: Immunoglobulins Market, Top Seven Markets, MG, Epidemiology, 2006-2012 61
  • Table 57: Immunoglobulins Market, Top Seven Markets, MG, Epidemiology Forecast, 2012-2019 61
  • Table 58: Immunoglobulins Market, Top Seven Markets, MG, Geographical Revenue ($m), 2006-2012 63
  • Table 59: Immunoglobulins Market, Top Seven Markets, MG, Geographical Revenue Forecast ($m), 2012-2019 64
  • Table 60: Immunoglobulins Market, Top Seven Markets, MMN, Revenue ($m), 2006-2012 66
  • Table 61: Immunoglobulins Market, Top Seven Markets, MMN, Revenue Forecast ($m), 2012-2019 66
  • Table 62: Immunoglobulins Market, Top Seven Markets, MMN, Annual Cost of Therapy ($), 2006-2012 67
  • Table 63: Immunoglobulins Market, Top Seven Markets, MMN, Annual Cost of Therapy Forecast ($), 2012-2019 67
  • Table 64: Immunoglobulins Market, Top Seven Markets, MMN, Epidemiology, 2006-2012 68
  • Table 65: Immunoglobulins Market, Top Seven Markets, MMN, Epidemiology Forecast, 2012-2019 68
  • Table 66: Immunoglobulins Market, Top Seven Markets, MMN, Geographical Revenue ($m), 2006-2012 70
  • Table 67: Immunoglobulins Market, Top Seven Markets, MMN, Geographical Revenue Forecast ($m), 2012-2019 71
  • Table 68: Immunoglobulins Market, Top Seven Markets, ITP, Revenue ($m), 2006-2012 73
  • Table 69: Immunoglobulins Market, Top Seven Markets, ITP, Revenue Forecast ($m), 2012-2019 73
  • Table 70: Immunoglobulins Market, Top Seven Markets, ITP, Annual Cost of Therapy ($), 2006-2012 74
  • Table 71: Immunoglobulins Market, Top Seven Markets, ITP, Annual of Cost Therapy Forecast ($), 2012-2019 74
  • Table 72: Immunoglobulins Market, Top Seven Markets, ITP, Epidemiology, 2006-2012 75
  • Table 73: Immunoglobulins Market, Top Seven Markets, ITP, Epidemiology Forecast, 2012-2019 75
  • Table 74: Immunoglobulins Market, Top Seven Markets, ITP, Geographical Revenue ($m), 2006-2012 77
  • Table 75: Immunoglobulins Market, Top Seven Markets, ITP, Geographical Revenue Forecast ($m), 2012-2019 78
  • Table 76: Immunoglobulins Market, US, FDA-Approved IVIG Products by Therapeutic Indication, 1994-2013 80
  • Table 77: Immunoglobulins Market, Top Five European Countries, EMA-Approved IVIG Products by Therapeutic Indication, 2004-2013 80
  • Table 78: Immunoglobulins Market, Global, Phase III Pipeline Molecules, 2013 95
  • Table 79: Immunoglobulins Market, Global, Alzheimer's Disease, Pipeline Molecules, 2013 96
  • Table 80: Immunoglobulins Market, Grifols, Global, Marketed Immunoglobulin Products, 2013 104
  • Table 81: Immunoglobulins Market, India, PI, Marketed Products, 2013 110
  • Table 82: Immunoglobulins Market, India, GBS, Marketed Products, 2013 111
  • Table 83: Immunoglobulins Market, India, CLL, Marketed Products, 2013 111
  • Table 84: Immunoglobulins Market, India, CIDP, Marketed Products, 2013 111
  • Table 85: Immunoglobulins Market, India, ITP, Marketed Products, 2013 112
  • Table 86: Immunoglobulins Market, India, Reliance Life Sciences, Key Pipeline Products, 2012-2013 115
  • Table 87: Immunoglobulins Market, India, Zydus Cadila, Key Marketed Products, 2012-2013 116
  • Table 88: Immunoglobulins Market, India, Sun Pharmaceuticals, Generic Versions of Key Marketed Products, 2012-2013 117
  • Table 89: Immunoglobulins Market, China, Blood and Blood Products Industry, 1985-2012 119
  • Table 90: Immunoglobulins Market, Australia, IVIG Issued to Patients, by Therapeutic Indication, 2011 124
  • Table 91: Immunoglobulins Market, Australia, Marketed Products, CIDP, 2013 126
  • Table 92: Immunoglobulins Market, Australia, Marketed Products, CLL, 2013 126
  • Table 93: Immunoglobulins Market, Australia, Marketed Products, GBS, 2013 126
  • Table 94: Immunoglobulins Market, Australia, Marketed Products, ITP, 2013 126
  • Table 95: Immunoglobulins Market, Australia, Marketed Products, PI, 2013 127

List of Figures

  • Figure 1: Immunoglobulins Market, Top Seven Markets, Revenue Forecast ($bn), 2006-2019 13
  • Figure 2: Immunoglobulins Market, Top Seven Markets, Annual Cost of Therapy Forecast ($), 2006-2019 14
  • Figure 3: Immunoglobulins Market, US, Revenue Forecast ($bn), 2006-2019 17
  • Figure 4: Immunoglobulins Market, US, Annual Cost of Therapy Forecast ($), 2006-2019 19
  • Figure 5: Immunoglobulins Market, Top Five European Countries, Revenue Forecast ($m), 2006-2019 20
  • Figure 6: Immunoglobulins Market, Top Five European Countries, Annual Cost of Therapy ($), 2006-2019 22
  • Figure 7: Immunoglobulins Market, Japan, Revenue Forecast ($m), 2006-2019 23
  • Figure 8: Immunoglobulins Market, Japan, Annual Cost of Therapy ($), 2006-2019 24
  • Figure 9: Immunoglobulins Market, Top Seven Markets, Market Share by Therapeutic Indication (%), 2012 27
  • Figure 10: Immunoglobulins Market, Top Seven Markets, PI, Revenue Forecast ($bn), 2006-2019 29
  • Figure 11: Immunoglobulins Market, Top Seven Markets, PI, Annual Cost of Therapy Forecast ($), 2006-2019 31
  • Figure 12: Immunoglobulins Market, Top Seven Markets, PI, Geographical Revenue Forecast ($m), 2006-2019 36
  • Figure 13: Immunoglobulins Market, Top Seven Markets, GBS, Revenue Forecast ($m), 2006-2019 38
  • Figure 14: Immunoglobulins Market, Top Seven Markets, GBS, Annual Cost of Therapy Forecast ($), 2006-2019 39
  • Figure 15: Immunoglobulins Market, Top Seven Markets, GBS, Geographical Revenue Forecast ($m), 2006-2019 42
  • Figure 16: Immunoglobulins Market, Top Seven Markets, CLL, Revenue Forecast ($m), 2006-2019 45
  • Figure 17: Immunoglobulins Market, Top Seven Markets, CLL, Annual Cost of Therapy Forecast ($), 2006-2019 46
  • Figure 18: Immunoglobulins Market, Top Seven Markets, CLL, Geographical Revenue Forecast ($m), 2006-2019 49
  • Figure 19: Immunoglobulins Market, Top Seven Markets, CIDP, Revenue Forecast ($m), 2006-2019 52
  • Figure 20: Immunoglobulins Market, Top Seven Markets, CIDP, Annual Cost of Therapy Forecast ($), 2006-2019 53
  • Figure 21: Immunoglobulins Market, Top Seven Markets, CIDP, Geographical Revenue Forecast ($m), 2006-2019 56
  • Figure 22: Immunoglobulins Market, Top Seven Markets, MG, Revenue Forecast ($m), 2006-2019 59
  • Figure 23: Immunoglobulins Market, Top Seven Markets, MG, Annual Cost of Therapy Forecast ($), 2006-2019 60
  • Figure 24: Immunoglobulins Market, Top Seven Markets, MG, Geographical Revenue Forecast ($m), 2006-2019 63
  • Figure 25: Immunoglobulins Market, Top Seven Markets, MMN, Revenue Forecast ($m), 2006-2019 66
  • Figure 26: Immunoglobulins Market, Top Seven Markets, MMN, Annual Cost of Therapy Forecast ($), 2006-2019 67
  • Figure 27: Immunoglobulins Market, Top Seven Markets, MMN, Geographical Revenue Forecast ($m), 2006-2019 70
  • Figure 28: Immunoglobulins Market, Top Seven Markets, ITP, Revenue Forecast ($m), 2006-2019 73
  • Figure 29: Immunoglobulins Market, Top Seven Markets, ITP, Annual Cost of Therapy Forecast ($), 2006-2019 74
  • Figure 30: Immunoglobulins Market, Top Seven Markets, ITP, Geographical Revenue Forecast ($m), 2006-2019 77
  • Figure 31: Immunoglobulins Market, US, FDA-Approved Products by Therapeutic Indication, 2003-2013 79
  • Figure 32: Immunoglobulins Market, Australia, IVIG Issued (g/1,000 population), 2006-2012 123
  • Figure 33: Immunoglobulins Market, Australia, IVIG Issued to Patients, by Therapeutic Indication, 2011 124
Back to Top